0001209191-20-040670.txt : 20200702
0001209191-20-040670.hdr.sgml : 20200702
20200702185442
ACCESSION NUMBER: 0001209191-20-040670
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200623
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kihara James
CENTRAL INDEX KEY: 0001816160
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 201011501
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 3611 VALLEY CENTRE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-06-23
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001816160
Kihara James
C/O ACADIA PHARMACEUTICALS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Principal Accounting Officer
Employee Stock Option (Right to Buy)
41.71
2030-04-06
Common Stock
32302
D
Restricted Stock Units
Common Stock
5955
D
25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
/s/ James K. Kihara
2020-07-02
EX-24.3_926451
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby authorizes each of
Austin D. Kim and/or Martin Choy to execute for and on behalf of the
undersigned, in the undersigned's capacity as an officer of ACADIA
Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments
thereto, and cause such form(s) to be filed with the Securities and Exchange
Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934,
relating to the undersigned's beneficial ownership of securities in the Company.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or substitute or
substitutes of such attorney-in-fact, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorney-in-fact, in serving in such
capacity at the request of the undersigned, is not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 2nd day of July, 2020.
/s/ James K. Kihara